While plasma-derived protein biomarkers can provide earlier and better diagnosis for more effective treatments, very few protein biomarkers identified using proteomics have been introduced in the clinical practice. This is primarily due to immense complexities associated with plasma/serum analysis.
Why choose Tymora Analytical plasma proteomics/PTMs?
- Our recently published manuscript in PNAS demonstrates for the first time the feasibility to identify thousands of phosphoproteins in plasma extracellular vesicles (EVs).
- On average, using 1mL of plasma as the starting material, we can routinely identify more than 3,000 unique phosphopeptides, representing >1,200 unique phosphoproteins.
- The identification numbers are significantly better than anything previously reported (highest previously reported number – 82 plasma EV phosphoproteins).
- The analysis is based on comprehensive profiling of EVs secreted into blood by all cells, with diseased cells/tumors producing unique EVs with specialized cargo.
- Our approach is the first and only method to successfully demonstrate the feasibility of developing plasma-derived EV phosphoproteins for disease profiling.